Related Experiment Video
Updated: Jan 22, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Mild behavioral impairment is linked to worse cognition and brain atrophy in Parkinson disease
Eun Jin Yoon1, Zahinoor Ismail1, Alexandru Hanganu1
1From the Department of Clinical Neurosciences (E.J.Y., Z.I., A.H., M.K., T.H., J.C., I.K., J.R.S., D.M., S.F., O.M.) and Departments of Psychiatry and Community Health Sciences (Z.I.), University of Calgary; Hotchkiss Brain Institute (E.J.Y., Z.I., A.H., M.K., T.H., J.C., I.K., J.R.S., D.M., S.F., O.M.), Cumming School of Medicine, Calgary, Alberta; Centre de Recherche (A.H., O.M.), Institut Universitaire de Gériatrie de Montréal; and Department of Psychology (A.H.), University of Montréal, Québec, Canada.
Objective:
To evaluate the associations of mild behavioral impairment (MBI) with cognitive deficits and patterns of gray matter changes in Parkinson disease (PD).
Methods:
Sixty patients with PD without dementia and 29 healthy controls underwent a cognitive neuropsychological evaluation and structural MRI scan. MBI was evaluated with the MBI Checklist (MBI-C), a rating scale designed to elicit emergent neuropsychiatric symptoms in accordance with MBI criteria. We divided the patients with PD into 2 groups: 1 group with high MBI-C scores (PD-MBI) and the other with low MBI-C scores (PD-noMBI).
Results:
Among 60 patients with PD, 20 were categorized as having PD-MBI (33.33%). In healthy controls, no participants met the MBI cut-point threshold. The PD-MBI group had significantly lower Montreal Cognitive Assessment and z scores in all 5 domains and the global score compared to healthy controls and those with PD-noMBI. In addition, all cognitive domains except language and global cognition negatively correlated with the MBI-C total score in all patients with PD. For cortical structures, the PD-MBI group revealed middle temporal cortex thinning and decreased volume compared with the PD-noMBI group, and decreased volume in this area negatively correlated with the MBI-C total score.
Conclusions:
The impaired cognitive function over all domains and atrophy in the temporal area in the PD-MBI group are in line with posterior cortical circuit deficits in PD, which have been associated with a faster rate of progression to dementia. These initial results suggest that MBI might be an early and important marker for incident cognitive decline and dementia in patients with PD.
Insights
Mild behavioral impairment (MBI) is linked to cognitive decline and temporal lobe gray matter changes in Parkinson disease (PD). MBI may serve as an early indicator of cognitive impairment and dementia risk in PD patients.
Area of Science:
- Neuroscience
- Neurology
- Psychiatry
Background:
- Parkinson disease (PD) is a neurodegenerative disorder.
- Mild behavioral impairment (MBI) is increasingly recognized in PD.
- The relationship between MBI, cognitive function, and brain structure in PD requires further investigation.
Purpose of the Study:
- To investigate the association between MBI and cognitive deficits in Parkinson disease.
- To examine patterns of gray matter changes in the brains of PD patients with and without MBI.
- To determine if MBI can predict cognitive decline and dementia in PD.
Main Methods:
- Sixty PD patients and 29 healthy controls underwent cognitive testing and structural MRI.
- MBI was assessed using the MBI Checklist (MBI-C).
- PD patients were categorized into high (PD-MBI) and low (PD-noMBI) MBI-C score groups.
Main Results:
- One-third of PD patients (33.33%) exhibited MBI (PD-MBI group).
- The PD-MBI group showed significantly poorer cognitive performance across multiple domains compared to controls and PD-noMBI.
- PD-MBI was associated with middle temporal cortex thinning and volume reduction, correlating with MBI severity.
Conclusions:
- Cognitive impairment and temporal lobe atrophy in PD-MBI align with posterior cortical circuit deficits.
- These deficits are linked to an accelerated progression to dementia.
- MBI may represent an early and significant biomarker for cognitive decline and dementia in Parkinson disease.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Cognition and Behavior
Parkinson's Disease: Overview
Cognitive Dissonance
Causes of Social Behavior II: Cognitive Processes
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

